Listed

PharmaCyte Biotech, Inc.: Form 10-K for the period ended Apr 30, 2022

Filed with the SEC on Jul 28, 2022 and accepted by EDGAR at Jul 28, 2022, 17:29 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-04-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2021-05-01 to 2022-04-30$0us-gaap:Revenues
Research and development12 months2021-05-01 to 2022-04-30$690.9kus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2021-05-01 to 2022-04-30−$4.4mus-gaap:OperatingIncomeLoss
Interest expense12 months2021-05-01 to 2022-04-30$509us-gaap:InterestExpense
Income tax12 months2021-05-01 to 2022-04-30$0us-gaap:IncomeTaxExpenseBenefit
Net income12 months2021-05-01 to 2022-04-30−$4.2mus-gaap:NetIncomeLoss
Diluted EPS12 months2021-05-01 to 2022-04-30−$0.27us-gaap:EarningsPerShareDiluted
Basic EPS12 months2021-05-01 to 2022-04-30−$0.27us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2021-05-01 to 2022-04-3015,521,654 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2021-05-01 to 2022-04-30−$4.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Current assetsAt period end2022-04-30$85.5mus-gaap:AssetsCurrent
Total assetsAt period end2022-04-30$90.6mus-gaap:Assets
Current liabilitiesAt period end2022-04-30$704.4kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-04-30$704.4kus-gaap:Liabilities
Shareholders' equityAt period end2022-04-30$89.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-22-005189. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.